Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical

Forbes - Martha will be focused initially on overseeing the Phase III program for Glinsuna(TM) (mitiglinide calcium hydrate) and Metgluna(TM) (mitiglinide plus metformin), which are being developed for the treatment of Type 2 diabetes, as well advancing the Read more